strategic plan
Lyell Immunopharma to Acquire ImmPact Bio, Discontinue Several Pipeline Programs
The firm will stop developing several of its own cell therapies to focus on advancing IMPT-314, a CAR T-cell therapy it is gaining by purchasing ImmPact.
Achilles Therapeutics Shuts Down Engineered Cell Therapy Program, Explores Cost-Cutting Measures
The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.
Allarity Therapeutics 'Retools' Pipeline to Focus on Stenoparib, Deprioritizes Ixempra, Dovitinib
The firm is shifting resources so it can quickly move the PARP/tankyrase inhibitor toward regulatory approval in advanced, biomarker-selected ovarian cancer.
Regeneron Pharmaceuticals Buys 2seventy Bio's R&D Pipeline for $5M Plus Milestone Payment
2seventy will now focus on growing the use of its singular commercially approved CAR T-cell product, Abecma, for which it is expecting lower-than-projected revenues in 2023.
Epizyme Exploring Tazverik Combinations in Basket Trials
The firm is hoping to identify new signals of activity for its lead compound in combination with other agents across a variety of solid and hematologic cancers.